ArticleEuropean clinical respiratory journal2020
Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment.
Article in European clinical respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Beyond Fatigue: The Fatigue Assessment Scale as a Potential Indicator of Long COVID Severity.Journal of clinical medicine · 2026Article
- Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease.Blood advances · 2025Article
- Evaluating fatigue and excessive daytime sleepiness: a comparative analysis of prevalence and correlating factors in interstitial lung disease patients and healthy controls.Annals of medicine · 2024Article
- Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single-arm, open-label nonrandomized study.Health science reports · 2023Article
- World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease.Frontiers in pharmacology · 2022Article
- Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Research highlights from the 2018 ERS International Congress: interstitial lung diseases.ERJ open research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.